NetraMark Holdings Inc. reports developments tied to artificial intelligence for clinical trial optimization and precision medicine in the pharmaceutical industry. Its recurring updates center on the NetraAI platform, which is designed to analyze complex clinical datasets, identify model-derived patient subgroups, and support patient stratification, enrichment strategies, and trial-design decisions.
Company news commonly covers pharmaceutical and research collaborations, contracts to analyze clinical trial data, peer-reviewed work, conference presentations, and clinical leadership additions. Reported therapeutic areas include central nervous system disorders, depression, Alzheimer’s disease, oncology, and regulated botanical wellness, with emphasis on explainable analytics, biomarker-guided insights, and responder or placebo-sensitive patient populations.
NetraMark (OTCQB: AINMF) announced acceptance of a peer‑reviewed paper, “Explainable AI‑Driven Precision Clinical Trial Enrichment,” in npj Digital Medicine on Dec 8, 2025. The study demonstrates the NetraAI platform using data from a National Institute of Mental Health Phase II ketamine trial in treatment‑resistant depression to identify interpretable Model Derived Subgroups (MDS) that could inform precision enrichment.
The paper highlights NetraAI’s use of explainable, mathematically grounded AI, dynamical‑systems modeling, long‑range‑memory feature learning, and LLM‑augmented explainability to improve clinical interpretability and trial decision‑making.
NetraMark (OTCQB: AINMF) announced four new contracts with a leading global pharmaceutical company, signed under an existing master services agreement, to apply its proprietary NetraAI platform to clinical data from four late-stage pivotal studies on November 18, 2025.
The engagements will perform multi-study analyses to identify explainable patient subpopulations driving treatment and placebo response and to quantify clinical and demographic drivers of trial variability. NetraAI is described as a mathematically-augmented, interpretable AI system intended to align with FDA expectations for explainable AI in clinical development.
NetraMark (OTCQB: AINMF) announced a new contract with a leading global biopharmaceutical company to apply its NetraAI platform to a Phase 3 clinical trial of a novel psychiatric medicine, dated November 3, 2025.
Under the agreement, NetraMark will deploy its proprietary AI methodology to analyze multi-dimensional clinical data and identify explainable patient subpopulations tied to treatment response, placebo response, and adverse events. The outputs are intended to support regulatory and market access planning and to inform future pivotal study design.
NetraAI uses a dynamical systems framework aimed at finding high-effect-size subgroups and translating them into clinically interpretable enrichment criteria for investigators, regulators, and clinicians.
NetraMark (OTCQB: AINMF) presented AI-driven analyses at ISCTM and ECNP on Oct 29, 2025 demonstrating NetraAI’s ability to identify responder subgroups and improve prediction in major depressive disorder trials.
Key readouts: ketamine responder Personas diverged from placebo by infusion 2 (separation 1.0) and ketamine responder cohesion rose from 25% to ~67%. In CAN-BIND escitalopram data NetraAI reduced clinical features to 8 key variables, isolated a highly predictive responder subgroup, and reported 91% accuracy for that subgroup using hypomethylation at three gene sites.
NetraMark Holdings (OTCQB: AINMF) has announced a strategic collaboration to advance glioblastoma (GBM) research using its NetraAI platform. The company has secured access to clinical and biomarker datasets from a leading U.S. academic medical center to develop therapeutic decision support tools for future GBM trials.
The collaboration will analyze longitudinal cerebrospinal fluid (CSF) proteomic datasets through six key objectives, including distinguishing GBM samples, differentiating tumor types, and studying disease recurrence patterns. The project aims to address the challenges in GBM treatment, where clinical trials face a 90% failure rate and patients have a median survival of just 15 months.
NetraMark Holdings (OTCQB: AINMF), an AI company specializing in clinical trial optimization, has appointed Dr. Jan Sedway as Senior Vice President of Clinical Science. Dr. Sedway brings over 20 years of leadership experience in clinical research and global operations, previously serving as Vice President of Clinical Development at Clario.
The appointment aligns with NetraMark's strategic expansion in the pharmaceutical industry, focusing on scaling its AI-powered solutions across psychiatry, oncology, and other therapeutic areas. Dr. Sedway's experience includes advancing digital biomarker solutions and driving operational excellence in global clinical trials, with previous leadership roles at Parexel and Syneos Health.
NetraMark Holdings (OTCQB: AINMF) has signed a contract with Asklepion Pharmaceuticals to deploy its NetraAI platform for analyzing results from a pivotal Phase III pediatric clinical trial. The study, CIT-003-01, evaluates the efficacy of intravenous L-citrulline in preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects.
NetraAI's technology will utilize explainable AI and generative modeling to optimize trial outcomes through enhanced patient stratification and identification of responder personas. The partnership aims to demonstrate L-citrulline's benefits in specific patient subgroups and inform future study designs.
NetraMark Holdings (OTCQB: AINMF), an AI company focused on clinical trials transformation, announced its CEO George Achilleos will attend Canaccord Genuity's 45th Annual Growth Conference from August 12-14, 2025, in Boston, Massachusetts.
The company's platform, NetraAI, is designed to enhance clinical development by identifying explainable patient subpopulations, uncovering drug response drivers, reducing placebo effects, and improving patient selection strategies. During the conference, the CEO will be available for one-on-one meetings with institutional investors, pharmaceutical sponsors, and strategic partners to discuss the platform's applications across therapeutic areas.
NetraMark Holdings (OTCQB: AINMF) has partnered with Pentara Corporation to launch an AI-powered site intelligence tool for enhancing clinical trial integrity. The collaboration introduces a novel system that calculates a Paradox Risk score to detect anomalous participant behavior and site-level irregularities using pre-randomization data.
The partnership combines NetraMark's AI technology with Pentara's expertise in clinical data analysis, particularly in degenerative diseases. The tool integrates information-theoretic variability, singleton occurrence frequencies, and co-association penalties to identify potential data integrity issues that could affect trial outcomes.
This strategic alliance aims to enable proactive risk mitigation, implement scalable site monitoring with real-time alerts, and enhance confidence in efficacy outcomes across heterogeneous clinical trials.
NetraMark Holdings (OTCQB: AINMF) has entered into an agreement with AlgoTherapeutix (AlgoTx) to enhance clinical trial design for ATX01, a treatment for chemotherapy-induced peripheral neuropathy (CIPN). NetraMark will deploy its NetraAI platform to analyze patient-level data from the ATX01 program.
The collaboration aims to leverage NetraAI's unique technology to identify responder personas, explore drug and placebo response variables, and develop enrichment strategies for future trials. The partnership will focus on creating customized AI models and interactive tools that enable hypothesis testing and precise characterization of patient subpopulations, with the goal of generating validated, explainable insights for regulatory submission.